Navigation Links
Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines
Date:8/5/2008

ott also has donated more than eight million rapid HIV tests to help prevent mother-to-child HIV transmission.

Abbott and Abbott Fund have announced several efforts to expand access to treatment and care for children living with HIV/AIDS, including an additional investment of US$12 million in grants and product donations this year.

For more information about Abbott's commitment to fighting HIV/AIDS, please visit http://www.abbott.com/hiv.

About Kaletra

Indication

KALETRA (lopinavir/ritonavir) is a human immunodeficiency virus-1 (HIV-1) protease inhibitor. KALETRA is always used in combination with other anti-HIV-1 medicines for the treatment of HIV-1 infection. KALETRA is a combination of two medicines, lopinavir and ritonavir. KALETRA is for adults and for children age six months and older.

Important Safety Information

KALETRA does not cure HIV-1 infection or AIDS and does not reduce the risk of passing HIV-1 to others.

KALETRA must not be taken by patients who have had an allergic reaction to KALETRA or any of its ingredients.

Taking KALETRA with certain drugs can cause serious problems or death. KALETRA must not be taken with dihydroergotamine, ergonovine, ergotamine or methylergonovines such as Cafergot(R), Migranal(R), D.H.E. 45(R), ergotrate maleate, and methergine, as well as Halcion(R) (triazolam), Orap(R) (pimozide), Propulsid(R) (cisapride), or Versed(R) (midazolam).

KALETRA must not be taken with rifampin, also known as Rimactane(R), Rifadin(R), Rifater(R), or Rifamate(R); St. John's Wort (hypericum perforatum); Mevacor(R) (lovastatin), or Zocor(R) (simvastatin).

There are drug-drug interactions with the potential for risk of serious or life-threatening side effects. Alterations in dose, increased monitoring of drug levels in the blood, or increased observations for side effects may be recommended when KALETRA is taken with: L
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy
2. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
3. Tablet PC Technology Helps Doctors and Patients Focus on Chemotherapy Side Effects, According to Thomson Healthcare Study
4. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
5. New Data Show Improvements in Work Performance in Patients with Chronic Insomnia Treated with AMBIEN CR(R) (zolpidem tartrate extended-release) Tablets CIV
6. A Phase II, Randomized, Double Blind, Placebo-Controlled Dose-Escalating Study, Meets the Clinical Endpoints of MTR106 Tablets During the Treatment of Acute Migraine Attacks Without Aura in Females
7. UCB Announces Positive Phase III Trial Results for Keppra XR(TM) (levetiracetam) Extended-Release Tablets
8. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
9. Keppra XR(TM) Extended-Release Tablets Filed with the FDA
10. Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets
11. Treximet(TM) (Sumatriptan and Naproxen Sodium) Tablets Approved by FDA for Acute Treatment of Migraine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... BETHESDA, Md. , Sept. 30, 2014 ... "Company") (Nasdaq: CHDX ) today announced the ... ("Healthy Harmony") for $24.00 per share in cash.  Healthy ... (Group) Co., Ltd. ("Fosun") and Ms. Roberta Lipson ... previously announced merger agreement was adopted by Chindex,s stockholders ...
(Date:9/29/2014)... PARIS , Sept. 30, 2014 /PRNewswire/ ... SAN and NYSE: SNY) today announced that a Phase ... blocks IL-4 and IL-13 signaling, met all primary and ... nasal polyps (CSwNP) who did not respond to intranasal ... of dupilumab for use in the treatment of another ...
(Date:9/29/2014)... CHICAGO , Sept. 29, 2014 ... clinical trials are conducted according to good clinical ... the HOPA Investigational Drug Service Best Practice Standards, ... best practice standards and guidance for pharmacists and ... Drug Service Best Practice Standards emphasizes the critical ...
Breaking Medicine Technology:Chindex Completes Go-Private Transaction With Healthy Harmony Holdings, L.P. 2Chindex Completes Go-Private Transaction With Healthy Harmony Holdings, L.P. 3Chindex Completes Go-Private Transaction With Healthy Harmony Holdings, L.P. 4Chindex Completes Go-Private Transaction With Healthy Harmony Holdings, L.P. 5Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 2Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 3Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 4Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 5Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 6Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 7HOPA Introduces First Investigational Drug Service Best Practice Standards For Institutions And Infusion Clinics 2HOPA Introduces First Investigational Drug Service Best Practice Standards For Institutions And Infusion Clinics 3
... , SAN DIEGO, Oct. 7 CareFusion Corporation (NYSE: CFN ... fiscal 2010 on Tuesday, Nov. 10 following the close of trading ... a webcast and conference call on Nov. 10 at 2:00 pm ... its first quarter, ended on Sep. 30, 2009. To access the ...
... Endoscopy, Inc. (Pink Sheets: SNDY) is pleased to announce ... be demonstrated at the 95th Annual American College of ... Illinois. During the Breast Ductoscopy for the General Surgeon ... to hands-on skill stations that will provide the core ...
Cached Medicine Technology:CareFusion Will Host An Earnings Conference Call on November 10, 2009 to Discuss the Results for the First Quarter of Fiscal 2010 2Solos Endoscopy, Inc.'s MammoView(TM) Product Line to be Demonstrated at the 95th Annual American College of Surgeons Clinical Congress 2
(Date:9/30/2014)... York, New York (PRWEB) September 30, 2014 ... and Co-Founder of Hudson Allergy , will discuss ... with food allergies and other special dietary restrictions at ... for Restaurateurs & Food Service Professionals, October 21 in ... speaking on this incredibly important topic to such an ...
(Date:9/30/2014)... Up to 45% of the population ... alone have sleep apnea. Of these, only 10% have ... cannot tolerate their prescribed medical device known as CPAP ... – which supports the airway during sleep. , In ... valuable, and increasingly difficult to get. Snoring and sleep ...
(Date:9/30/2014)... of high-dose vitamin D3 compared with placebo did not ... length of stay, hospital mortality, or the risk of ... deficiency who were critically ill, according to a study ... posted early online to coincide with its presentation at ... , A high prevalence of low vitamin D ...
(Date:9/30/2014)... September 30, 2014 Youth Town’s annual ... 10 a.m. to 2 p.m. at the Youth Town ... the World sponsors this family-oriented festival, which will offer ... festival will feature a car show, arts and crafts ... and children’s games. Also, Lightning McQueen and Mater from ...
(Date:9/30/2014)... San Francisco, CA (PRWEB) September 30, 2014 ... places its main focus on ranking and reviewing all ... This website has officially announced the best liquid foundation ... Youth Liberator Serum Foundation is named as the best ... foundations cover drugstore as well as high end brands, ...
Breaking Medicine News(10 mins):Health News:Hudson Allergy’s Dr. Julie Kuriakose to Speak at Prestigious Food Allergy Conference in New York City 2Health News:Hudson Allergy’s Dr. Julie Kuriakose to Speak at Prestigious Food Allergy Conference in New York City 3Health News:Snoring: Robs People and Their Bed Partners of the Rest They Need to Face Daily Challenges 2Health News:Snoring: Robs People and Their Bed Partners of the Rest They Need to Face Daily Challenges 3Health News:High-dose vitamin D for ICU patients who are vitamin D deficient does not improve outcomes 2Health News:Yves Saint Laurent is Named As Best Liquid Foundation 2014 2
... Black adults are more likely to smoke than white ... show that fewer black youths than whites begin smoking as ... lower rates of smoking among black teens may be the ... and establishing clearly defined consequences for not following those guidelines. ...
... Sale DENVER, May 14 arc Thrift Stores will ... developmental disabilities at this year,s Starfish and Dreams Celebration ... Hope Hernandez Salazar, Larry and Michelle Trujillo and Kirk ... people in Colorado who live with physical and cognitive ...
... Policy Issues, from Personalized Medicine to BiosimilarsWASHINGTON, May 14 ... today, John C. Lechleiter, Ph.D., chairman and CEO of ... said that federal policymakers, attention to access, quality and ... on innovation - or the results could include "unintended ...
... allows student doctors to practice operations and other procedures ... just as pilots practice for emergencies on aircraft simulators. ... by avoiding first-time mistakes being made on live patients. ... learn new skills on simulators instead of on humans? ...
... Medical Equipment Suppliers Who Account for 85% of Suppliers in ... that the independent home medical equipment (HME) providers have a ... for any healthcare reform initiative, a group of home medical ... Suppliers, LLC (CSI: HME) . This non-profit business league was ...
... Medical Schools to Provide Testing Tools to Students ... -- McGraw-Hill Professional, a leading global provider ... communities, has relaunched USMLEasy ( http://www.usmleasy.com ... preparation resource from McGraw-Hill that offers institutional access. ...
Cached Medicine News:Health News:Parental guidelilnes, consequences may be why fewer black teens smoke than whites 2Health News:arc Thrift Stores to Honor Individuals and Businesses Who Support People With Developmental Disabilities 2Health News:Lilly Chairman & CEO Lechleiter Says Innovation Is Vital-But-Missing Plank in Health Reform Debate 2Health News:Lilly Chairman & CEO Lechleiter Says Innovation Is Vital-But-Missing Plank in Health Reform Debate 3Health News:Lilly Chairman & CEO Lechleiter Says Innovation Is Vital-But-Missing Plank in Health Reform Debate 4Health News:New Organization Formed To Save Independent Medical Equipment Suppliers 2Health News:New Organization Formed To Save Independent Medical Equipment Suppliers 3Health News:New Online Institutional Resource in Test Preparation Launched by McGraw-Hill Professional 2Health News:New Online Institutional Resource in Test Preparation Launched by McGraw-Hill Professional 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: